Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.

about

Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor.

P2860

Q55259703-52056D9D-2C45-4AED-B90B-14900B9D8FFF

P2860

Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.

Item

http://www.wikidata.org/entity/Q38643965

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Biological anti-TNF drugs: imm ...... nt failure and adverse events.

@en

type

Item

label

Biological anti-TNF drugs: imm ...... nt failure and adverse events.

@en

prefLabel

Biological anti-TNF drugs: imm ...... nt failure and adverse events.

@en

P1476

Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events

@en

P2093

Klaus Bendtzen

http://www.w3.org/2001/XMLSchema#string

Mônica Simon Prado

http://www.w3.org/2001/XMLSchema#string

P2860

Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials

Continuous cultures of fused cells secreting antibody of predefined specificity

Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection

Replacing the complementarity-determining regions in a human antibody with those from a mouse

Human immune response to recombinant human proteins.

Therapeutic antibodies for human diseases at the dawn of the twenty-first century.

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study.

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

PEGylated antibodies and antibody fragments for improved therapy: a review.

Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics.

P304

985-995

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17425255.2017.1360280

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Luis E. Andrade

P577

2017-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28772079

http://www.w3.org/2001/XMLSchema#string

P921

TNF inhibitor

TNF

Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.

about

P2860

P2860

Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921